News
August 3, 2020

Manufacturer Settles Alleged Kickback and False Claims Violations Related to Research Grants

August 3, 2020— Pacira Pharmaceuticals has agreed to pay $3.5 million to resolve allegations that it paid kickbacks to doctors in the form of sham research grants, according to the Department of Justice (DoJ). The allegations arose from a whistleblower suit filed under the False Claims Act (FCA) claiming that the grants were designed to induce recipients to prescribe EXPAREL, the company’s non-opioid analgesic product.

According to documents filed in this case, for over 2 years Pacira paid disguised kickbacks in the form of research and other grants to health care providers. The government contended that from late 2012 to early 2015 Pacira targeted physicians and their respective hospitals with the intent of inducing sales of its then newly-launched product. 

The government’s theory of the case was that Pacira caused the submission of false claims in violation of the False Claims Act (31 U.S.C. § 3730(b)) and Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) by using sham research grants to induce sales of EXPAREL, which it knew would be used in procedures reimbursed by Medicare and Medicaid.

The research grants appear to have lacked many industry-standard compliance controls associated with legitimate research, including:

  • Limitations on Commercial Involvement: According to DoJ, the research grants in question were typically initiated by Pacira sales representatives or marketing executives, who discussed internally their sales goals in connection with the grants.
  • Demonstrating Legitimate Research Need: It appears Pacira did not document why it needed the research, a reg flag that calls into question their legitimacy.
  • Implementing Contractual Controls: The documents indicated that Pacira did not contractually require that grant recipients adhere to the proposed research topic or achieve certain milestones before payment. 
  • Setting FMV Payments: Nor did Pacira appear to document the fair market value of the payments, which is standard industry practice for bone fide HCP engagements.
  • Documentation of Work Performed: In many instances, the government alleged that Pacira did not follow-up with the grant recipient to ensure that the work was being performed. The government alleged that the grant recipient did no work at all in some cases.

Perhaps most egregious is the allegation that Pacira executives coached grant recipients and other employees on how to avoid internal scrutiny of the grant payments.

Pacira did not admit liability in the matter and denied all allegations. Additional details on the case are available in the settlement agreement in which the government expressly reserves all rights to seek exclusion from Medicare, Medicaid, and other Federal health care programs against Pacira and/or its officers, directors and employees.

(Settlement Agreement: https://www.justice.gov/usao-nj/press-release/file/1298661/download)

If you have questions regarding the alert or implementing appropriate controls related to legitimate research grants, please contact Razor Legal Solutions here (https://www.razorlegalsolutions.com/contact).


A picture containing guitar, flower, drawing, lightDescription automatically generated


This alert provides information as a service to clients and other friends of the firm for educational purposes only. It should not be construed or relied upon as legal advice, and it does not create an attorney-client relationship.